NCT05678673Phase 3Active not recruiting

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Study sponsor: Exelixis

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-12-15Estimated
Enrollment · participants317Actual
Source updated2026-07-29Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: Jul 2025. After: 15 Dec 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview